HC Wainwright Reiterates Buy Rating for IceCure Medical (NASDAQ:ICCM)

HC Wainwright reaffirmed their buy rating on shares of IceCure Medical (NASDAQ:ICCM) in a report published on Wednesday,Benzinga reports. The brokerage currently has a $2.50 price objective on the stock.

Separately, Alliance Global Partners upgraded IceCure Medical to a “strong-buy” rating in a report on Friday, November 1st.

IceCure Medical Stock Up 5.8 %

IceCure Medical stock opened at $0.83 on Wednesday. IceCure Medical has a twelve month low of $0.48 and a twelve month high of $1.57. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.54 and a current ratio of 2.97. The firm has a market cap of $37.96 million, a PE ratio of -2.77 and a beta of 0.48. The firm’s 50 day moving average price is $0.64 and its two-hundred day moving average price is $0.73.

Hedge Funds Weigh In On IceCure Medical

A hedge fund recently bought a new stake in IceCure Medical stock. Renaissance Technologies LLC bought a new position in IceCure Medical Ltd (NASDAQ:ICCM) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 66,400 shares of the company’s stock, valued at approximately $49,000. Renaissance Technologies LLC owned approximately 0.15% of IceCure Medical as of its most recent SEC filing. 0.62% of the stock is owned by institutional investors and hedge funds.

About IceCure Medical

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.